Guggenheim Capital LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.9% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 315,461 shares of the medical research company’s stock after acquiring an additional 17,552 shares during the period. Guggenheim Capital LLC’s holdings in Thermo Fisher Scientific were worth $59,899,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Icon Wealth Partners LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $105,000. Bank of Nova Scotia Trust Co. acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at $106,000. Keeler Thomas Management LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $106,000. Virtue Capital Management LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $127,000. Finally, SeaCrest Wealth Management LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $195,000. Institutional investors own 87.67% of the company’s stock.
In other Thermo Fisher Scientific news, Director William G. Parrett sold 1,000 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $209.80, for a total transaction of $209,800.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Gregory J. Herrema sold 33,327 shares of the stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the sale, the senior vice president now directly owns 60,471 shares in the company, valued at approximately $13,285,478.70. The disclosure for this sale can be found here. In the last three months, insiders have sold 98,827 shares of company stock worth $20,193,272. Insiders own 0.49% of the company’s stock.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 EPS for the quarter, topping analysts’ consensus estimates of $2.66 by $0.13. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The firm had revenue of $6.05 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same quarter in the prior year, the firm earned $2.41 EPS. The company’s revenue was up 22.1% on a year-over-year basis. analysts expect that Thermo Fisher Scientific Inc. will post 10.81 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Thursday, March 15th will be issued a dividend of $0.17 per share. The ex-dividend date is Wednesday, March 14th. This represents a $0.68 dividend on an annualized basis and a yield of 0.32%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s dividend payout ratio is currently 10.71%.
A number of equities analysts have recently issued reports on the stock. Leerink Swann restated an “outperform” rating and issued a $200.00 price objective (down previously from $216.00) on shares of Thermo Fisher Scientific in a research note on Monday, December 4th. Morgan Stanley increased their target price on shares of Thermo Fisher Scientific from $223.00 to $227.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. BTIG Research initiated coverage on shares of Thermo Fisher Scientific in a research report on Friday, January 5th. They set a “buy” rating and a $230.00 target price for the company. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “sell” rating to a “hold” rating in a research report on Saturday, January 20th. Finally, Barclays increased their target price on shares of Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Two analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $220.50.
ILLEGAL ACTIVITY WARNING: “Guggenheim Capital LLC Acquires 17,552 Shares of Thermo Fisher Scientific Inc. (TMO)” was published by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3261778/guggenheim-capital-llc-acquires-17552-shares-of-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.